In Endo Pharmaceuticals Inc. v. Teva
Pharmaceuticals USA, Inc., No. 2017-1240 (Fed. Cir. Mar.
28, 2019), the Federal Circuit reversed a decision of invalidity
under 35 U.S.C. § 101, holding instead that the method of
treatment claims were patent eligible for claiming an application
of a natural relationship and not the natural relationship
itself.
Endo's asserted patent taught a method for adjusting the
oxymorphone dose in patients with renal impairment. Actavis, a
co-defendant in the case, moved to dismiss Endo's infringement
claims, arguing that the claims were ineligible as directed to a
natural law under 35 U.S.C. § 101. The district court
dismissed after finding the claims ineligible using the two-step
Alice/Mayo framework.